Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 o Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (IRS ...

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +566.67%. A quarter ago, it was expected that this company would post earnings of $0.03 per share when it actually produced earnings of $0.24, delivering a surprise of +700%.Over the last four quarters, the company ...

OptimizeRx (NasdaqCM:OPRX) Q3 2025 Earnings Call November 06, 2025 04:30 PM ET Speaker0The Street and also to our clients and investors that we're going to give more visibility on our visibility into the future as we've been migrating more toward a predictive model. We've quoted in the past descriptive momentum. So we're going to continue to push that throughout the remainder of the year. And as a result of that, we're now getting more visibility into the out years, including 2026. In terms of the RFP situa ...

million and $22 million OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance - Q3 revenue of $26.1 million, increased 22% year-over-year - Q3 gross profit increased 30% year-over-year to $17.5 million Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million - Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range bet ...

-   Q3 revenue of $26.1 million, increased 22% year-over-year-   Q3 gross profit increased 30% year-over-year to $17.5 million-   Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million-   Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range between $19 million and $22 million-   Paid off an incremental $2 million in principal from term loan subsequent to ...

Core Insights - OptimizeRx Corp. will hold a conference call on November 6, 2025, to discuss its third-quarter financial results for the period ending September 30, 2025 [1][2] - The call will include a question-and-answer session and will be accessible via toll-free and international numbers [2] - A replay of the call will be available for 12 months on the company's investor relations website [3] Company Overview - OptimizeRx is a leading healthcare technology company focused on enhancing connections between life science brands, patients, and healthcare providers [4] - The company utilizes AI-driven tools such as the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to facilitate timely and relevant engagement [4] - OptimizeRx emphasizes privacy-safe, patient-centric technology to ensure impactful interactions that deliver therapies to patients effectively [5] - The company is headquartered in Waltham, Massachusetts, and collaborates with major pharmaceutical and life sciences companies to improve healthcare outcomes [5]

Many people see OptimizeRx Corporation (NASDAQ: OPRX ) as a simple message platform inside Electronic Health Record (EHR) Systems or an intermediary that connects pharma companies with doctors. Our thesis says that OPRX transforms itself from just a delivery channel to a clinical dataAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or s ...

Group 1 - OptimizeRx Corporation (NASDAQ: OPRX) is perceived as a simple messaging platform within Electronic Health Record (EHR) systems, but it is evolving beyond just being a delivery channel [1] - The company aims to transform its role to connect pharmaceutical companies with healthcare providers more effectively [1]

Core Viewpoint - OptimizeRx Corp. (OPRX) is identified as a strong momentum stock with a Zacks Rank of 1 (Strong Buy) and a Momentum Style Score of B, indicating potential for significant near-term gains [4][12]. Company Performance - OPRX shares have increased by 3.19% over the past week, while the Zacks Computer - Software industry has declined by 1.15% during the same period [6]. - Over the last quarter, OPRX shares have risen by 40.18%, and over the past year, they have surged by 150.07%, significantly outperforming the S&P 500, which has moved 8.57% and 18.94% respectively [7]. - The average 20-day trading volume for OPRX is 371,193 shares, indicating a bullish trend as the stock is rising with above-average volume [8]. Earnings Outlook - In the past two months, four earnings estimates for OPRX have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $0.53 to $0.67 [10]. - For the next fiscal year, four estimates have also moved upwards without any downward revisions, suggesting a positive earnings outlook [10].

Group 1: OptimizeRx Performance - OptimizeRx (OPRX) reported second-quarter 2025 revenues of $29.2 million, reflecting a 55% year-over-year increase, with earnings per share at 24 cents, surpassing consensus estimates [1] - The company achieved strong adjusted EBITDA of $5.8 million and expanding gross margins, indicating operational leverage, while raising full-year revenue guidance to $104-$108 million [1] - Contracted revenues increased by over 30%, demonstrating growing customer confidence in OPRX's integrated solutions [1] Group 2: Strategic Focus and Market Position - OPRX's strategy centers on AI-driven workflow integration, utilizing an omnichannel platform that connects physicians, patients, and life sciences firms in real time [2] - The integration is crucial as the pharmaceutical industry focuses on efficient script lift and reduced abandonment amid regulatory uncertainty and a shift towards specialty medications [3] - Management noted that operating expenses remained flat despite double-digit top-line growth, indicating meaningful leverage from its scalable tech stack [3] Group 3: Future Outlook and Challenges - Part of the second-quarter outperformance was due to episodic managed service revenues, which are not expected to recur in the second half of the year [4] - OPRX's ability to serve both healthcare professionals (HCP) and direct-to-consumer (DTC) markets at scale provides a competitive advantage, but sustaining momentum will require expanding multiyear subscription contracts and managing customer concentration risk [4] - Average revenues per top-20 pharma manufacturer increased to $3.1 million, with mid-tier clients scaling faster than top-20 accounts, broadening the revenue base [5] Group 4: Industry Trends and Competitors - Omnicell (OMCL) is enhancing its digital health strategy through the Intelligence-Enabled Pharmacy vision, scaling its OmniSphere platform, which is a cloud-based, AI-powered solution for predictive analytics and real-time medication inventory management [6] - OMCL's Advanced Services suite integrates automation, analytics, and remote pharmacy services to optimize clinical and financial outcomes for healthcare providers [7] - Teladoc Health (TDOC) is focusing on digital mental health through its BetterHelp platform and the acquisition of UpLift, which enhances therapy options and reduces out-of-pocket costs for users [8]